|
|
Post by savzak on Jan 12, 2015 13:20:45 GMT -5
I just listened to the SNY presentation and here's a summary of what he said regarding Afrezza:
Ease of use in diabetes care is essential. Needles and so on a problem. Need rapid onset for prandial so we partnered with MNKD. Al Mann is there in the audience. He recognized Al’s presence. He commented that device is so small compared to Exubera. Thinks Afrezza will be utilized either as a supplement or as a first line of treatment. He said We really believe this will satisfy a significant need. Afrezza will be a major component of our diabetes care portfolio.
I timed it. He talked about Afrezza for exactly 1 minute and 20 seconds. A nice reasonable presentation. Certainly no new information.
|
|
|
|
Post by mdcenter61 on Jan 12, 2015 14:34:53 GMT -5
Thanks, Savzak - well, Adam F. chose to write another hit piece based on that presentation; typical BS from the Street. Here we go again.
|
|
|
|
Post by daduke38 on Jan 12, 2015 14:43:46 GMT -5
Thanks, Savzak - well, Adam F. chose to write another hit piece based on that presentation; typical BS from the Street. Here we go again. Yeah, Savak sure had a different take the AF. |
|
|
|
Post by spiro on Jan 12, 2015 15:34:30 GMT -5
Savzak has it right. it was short and sweet. Afrezza launch is hopefully only weeks away and things should heat up rather nice during the next several month's.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 12, 2015 15:51:17 GMT -5
There were some positive, well known facts about Afrezza, but the presentation was as dry as dust and meat for the likes of Feuerstein.
|
|
|
|
Post by Chris-C on Jan 12, 2015 16:22:17 GMT -5
Thanks, Savzak - well, Adam F. chose to write another hit piece based on that presentation; typical BS from the Street. Here we go again. Yeah, Savak sure had a different take the AF. daDuke: It's getting so that I'm comforted and reassured when AF does what he does. If he ever does a 180 and starts saying positive things about MNKD, then I may start to worry. In other words, beware of wolves (or bears) in sheep's clothing. Be comforted when these characters act as the predators they are. Chris_C |
|
|
|
Post by kc on Jan 12, 2015 16:34:59 GMT -5
SNY needs Afrezza really badly since they don't even have approval on Toujeo yet. How did SNY allow themselves to get into this situation. Seems they really need a homerun from Affrezza since Lantus represents 22% of their offerings. This is an good view that JP Morgan's analyst had on current drugs and pipeline. Notice they show Afrezza at only having a 50% chance of sucess. Again everybody has discounted it being a productive offering by Sanofi. Does it scare or bother you? I am disapointed by not scared.  |
|
|
|
Post by in search of the truth on Jan 12, 2015 16:57:05 GMT -5
I hope that this does not mean that Sanofi only has a 50% confidence level of success in Afrezza! If so,we sold the product to the wrong partner! Why would Mannkind sell to somkeone who only had a 50% confidence level?
on a separate note, the LA times says this:
"MannKind is running three shifts at its Connecticut manufacturing plant to build inventory in anticipation of the rollout," Markey said. "Separately, we learned that Sanofi will hold meetings in late January to prepare its sales team for the official launch."
So, it looks like launch is not in the first month of the year. Makes you wonder how long it takes to launch a product? It has been approved for over 6 months already............ if I were Sanofi, I would want to start earning revenue as soon as possible...........
|
|
|
|
Post by kc on Jan 12, 2015 17:34:30 GMT -5
No this is the JP Morgan analyst James Gordon and Richard Vosser. they are based in London.
James D. Gordon
Pharmaceuticals / Biotechnology (Europe)
james.d.gordon@jpmorgan.com
James Gordon joined JPMorgan's European Pharmaceuticals team in February 2006. Prior to this, James spent two and half years working as an analyst in the management consulting department at IMS Health, specialising in the pharmaceutical industry. James holds a BSc in Genetics from University College London.
Richard Vosser
Head of Pharmaceuticals / Biotechnology (Europe)
richard.vosser@jpmorgan.com
Richard Vosser joined JPMorgan in June 2008 as Senior Analyst in the Healthcare team. Richard comes from Bear Stearns where he was an analyst covering the Pan-European pharmaceutical sector. Richard holds a masters degree (MSCi) in Chemistry and a degree (MA) in Natural Sciences both from Cambridge University. He is also a qualified chartered accountant. Prior to Bear Stearns Richard was a management consultant with Mitchell Madison Group and an accountant with KPMG.
2015 Global Biotech Outlook
Company Profiles from Our Global Biotech Universe -
What to Expect in 2015
Our Global Biotech Outlook highlights industry-specific trends that are relevant for
the year and our top picks from the Kasimov, Rama, Fye and Vosser/Gordon teams. In
this report, we provide one-page profiles for each company under J.P. Morgan’s global
coverage of the biotechnology industry, which consists of 26 names from the Kasimov
team, 16 names from the Rama team, 15 names from the Fye team, and 12 names from
the Vosser/Gordon team. The objective is to highlight what we expect from each
company in 2015, what the primary what the primary value drivers are for the year, and where we differ
from consensus expectations.
|
|
|
|
Post by BlueCat on Jan 12, 2015 17:43:51 GMT -5
I hope that this does not mean that Sanofi only has a 50% confidence level of success in Afrezza! If so,we sold the product to the wrong partner! Why would Mannkind sell to somkeone who only had a 50% confidence level? on a separate note, the LA times says this: "MannKind is running three shifts at its Connecticut manufacturing plant to build inventory in anticipation of the rollout," Markey said. "Separately, we learned that Sanofi will hold meetings in late January to prepare its sales team for the official launch." So, it looks like launch is not in the first month of the year. Makes you wonder how long it takes to launch a product? It has been approved for over 6 months already............ if I were Sanofi, I would want to start earning revenue as soon as possible........... I don't think this is a confidence level. If I read the numbers right, in first year, they project to attach to 50% of their target market, which is a total of over $3B. That's actually very high confidence. If I am reading it correctly. |
|
|
|
Post by in search of the truth on Jan 12, 2015 17:45:05 GMT -5
Right, sorry.... Glad it was JP Morgan's analysis and not Sanofi's. Just my frustration showing that no matter how convinced I am that Afrezza will succeed, it appears that MannKind and Sanofi are disfunctional in their efforts. I can't imagine why they have to be so withdrawn and secretive. I want them telling the world how great Afrezza is and launching commercials and touting the kinetics of the monomer and have a "big bang" launch but it wouldn't surprize me to hear that the product went on sale without as much as a whimper of fanfare.... maybe they need to have the marketing person present at these healthcare conferences...
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 12, 2015 17:47:03 GMT -5
SNY needs Afrezza really badly since they don't even have approval on Toujeo yet. How did SNY allow themselves to get into this situation. Seems they really need a homerun from Affrezza since Lantus represents 22% of their offerings. This is an good view that JP Morgan's analyst had on current drugs and pipeline. Notice they show Afrezza at only having a 50% chance of sucess. Again everybody has discounted it being a productive offering by Sanofi. Does it scare or bother you? I am disapointed by not scared. They are showing afrezza worth more than toujeo? |
|
|
|
Post by shortslaver on Jan 12, 2015 18:39:36 GMT -5
Well, they are giving Afrezza a 50/50 chance of being a successful drug. Sounds about right and a bit pessimistic I'd say, which is where you want the conventional wisdom to be if you're long right now. Low expectations are great for upside.
|
|
|
|
Post by mnholdem on Jan 13, 2015 5:55:20 GMT -5
Odd that they list Afrezza under Pharma Pipeline Phase III. It makes me think they are viewing Afrezza solely as a prandial to be used in combination with Toujeo. They are limiting Afrezza's target population, which I see as an error in their assessment.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 13, 2015 7:47:19 GMT -5
Well, they are giving Afrezza a 50/50 chance of being a successful drug. Sounds about right and a bit pessimistic I'd say, which is where you want the conventional wisdom to be if you're long right now. Low expectations are great for upside. That's not how I read it though it was hard to see the column titles. I read it as they get 50% of the value because they don't own the drug outright, not that it represented a chance of success. |
|
